Title:
THERAPEUTIC AGENT FOR MESENCHYMAL KRAS MUTATION–TYPE CANCERS
Document Type and Number:
WIPO Patent Application WO/2017/086332
Kind Code:
A1
Abstract:
Provided is a therapeutic agent having a novel mechanism against specific KRAS mutation–type cancers. The present invention provides a therapeutic agent for mesenchymal KRAS mutation–type cancers that comprises a fibroblast growth factor receptor 1 (FGFR1) inhibitor. The therapeutic agent is optimally administered in combination with a MAPK/ERK kinase (MEK) inhibitor. The present invention also provides a mesenchymal cancer cell detection reagent and a cell type determination reagent set that can be used as companion diagnostic agents.
Inventors:
EBI HIROMICHI (JP)
YANO SEIJI (JP)
KITAI HIDENORI (JP)
YANO SEIJI (JP)
KITAI HIDENORI (JP)
Application Number:
PCT/JP2016/083921
Publication Date:
May 26, 2017
Filing Date:
November 16, 2016
Export Citation:
Assignee:
NAT UNIV CORP KANAZAWA UNIV (JP)
International Classes:
A61K45/00; A61K45/06; A61P35/00; A61P43/00; G01N33/50
Domestic Patent References:
| WO2013146993A1 | 2013-10-03 |
Foreign References:
| JP2012522217A | 2012-09-20 | |||
| JP2014532647A | 2014-12-08 | |||
| JP2014033626A | 2014-02-24 |
Other References:
LEHNEN, N. C. ET AL.: "Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma", HISTOPATHOLOGY, vol. 63, 2013, pages 157 - 166, XP055246591, DOI: doi:10.1111/his.12115
OKUMURA, S. ET AL.: "Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers", CLINICAL CANCER RESEARCH, vol. 20, no. 16, 2014, pages 4193 - 4199, XP055508860, DOI: doi:10.1158/1078-0432.CCR-13-2365
EBI, H. ET AL.: "Both amplification and protein expression are requires to predict FGFR tyrosine kinase inhibitor sensitivity in lung cancer", CANCER RESEARCH, vol. 75, no. 15, August 2015 (2015-08-01), XP055596339, Retrieved from the Internet [retrieved on 20170125]
KITAI, H. ET AL.: "Epithelial-to- Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer", CANCER DISCOVERY, vol. 6, no. 7, 6 May 2016 (2016-05-06) - July 2016 (2016-07-01), pages 754 - 769, XP055596343, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-15-1377
WASSERMAN, J. K. ET AL.: "Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis", HEAD AND NECK PATHOL., vol. 10, January 2016 (2016-01-01), pages 279 - 285, XP036023164, DOI: doi:10.1007/s12105-015-0678-1
OKUMURA, S. ET AL.: "Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers", CLINICAL CANCER RESEARCH, vol. 20, no. 16, 2014, pages 4193 - 4199, XP055508860, DOI: doi:10.1158/1078-0432.CCR-13-2365
EBI, H. ET AL.: "Both amplification and protein expression are requires to predict FGFR tyrosine kinase inhibitor sensitivity in lung cancer", CANCER RESEARCH, vol. 75, no. 15, August 2015 (2015-08-01), XP055596339, Retrieved from the Internet
KITAI, H. ET AL.: "Epithelial-to- Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer", CANCER DISCOVERY, vol. 6, no. 7, 6 May 2016 (2016-05-06) - July 2016 (2016-07-01), pages 754 - 769, XP055596343, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-15-1377
WASSERMAN, J. K. ET AL.: "Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis", HEAD AND NECK PATHOL., vol. 10, January 2016 (2016-01-01), pages 279 - 285, XP036023164, DOI: doi:10.1007/s12105-015-0678-1
Attorney, Agent or Firm:
HIRAKI Yusuke et al. (JP)
Download PDF:
Previous Patent: LIGHTING DEVICE, LIGHTING SYSTEM, AND METHOD FOR MANUFACTURING LIGHTING DEVICE
Next Patent: VACUUM CHUCK
Next Patent: VACUUM CHUCK